drugset / Trial / NCT03142165
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants
RandomizedParallel-groupQuadruple-blindScreening
Summary
The purpose of this study is to assess the safety and tolerability of BMS-986263 in healthy volunteers.
Timeline
- Start
- 2017-05-11
- Primary completion
- 2017-11-29
- Completion
- 2017-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986263 | Small interfering RNA (siRNA) | 90 mg | Intravenous |
| Background | Diphenhydramine | Unknown | 50 mg | Intravenous |
| Background | Famotidine | Other / unclassified | 20 mg | Intravenous |
Indications
No indication recorded.